oxazoles has been researched along with cardiovascular agents in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, HW; Ho, JK; Jones, RL; Lam, WL; Qian, YM; Wise, H; Wong, HN; Yim, AP | 1 |
| Blue, DR; Dillon, MP; Eglen, RM; Jasper, JR; Lesnick, JD; MacLennan, SJ; Zhu, QM | 1 |
| CAIN, CK; PLAMPIN, JN | 1 |
| Bajaj, M; Birnbaum, Y; Chen, H; Nanhwan, MK; Qian, J; Ye, Y | 1 |
4 other study(ies) available for oxazoles and cardiovascular agents
| Article | Year |
|---|---|
Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
Topics: Acetates; Aged; Cardiovascular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoprostenol; Fatty Acids; Humans; Iloprost; Imidazoles; Indoles; Middle Aged; Muscle, Smooth, Vascular; Oxazoles; Phenoxyacetates; Platelet Aggregation Inhibitors; Prostaglandins, Synthetic; Pulmonary Artery; Receptors, Epoprostenol; Receptors, Prostaglandin; Structure-Activity Relationship; Vasoconstrictor Agents; Vasodilator Agents | 1997 |
Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice.
Topics: Adrenergic alpha-Antagonists; Amino Acid Substitution; Animals; Binding, Competitive; Blood Pressure; Cardiovascular Agents; Cell Line; Clonidine; Consciousness; Dogs; Heart Rate; Humans; Imidazoles; In Vitro Techniques; Isoquinolines; Male; Mice; Mice, Inbred Strains; Mice, Transgenic; Mutation; Naphthyridines; Oxazoles; Quinolizines; Radioligand Assay; Receptors, Adrenergic, alpha-2; Recombinant Fusion Proteins; Rilmenidine; Saphenous Vein; Tritium | 1999 |
SYNTHESIS OF METABOLIC PRODUCTS OF BENZOXAZOLES.
Topics: Benzoxazoles; Cardiovascular Agents; Chemistry, Pharmaceutical; Metabolism; Mice; Muscle Relaxants, Central; Oxazoles; Pharmacology; Research; Zoxazolamine | 1963 |
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cardiovascular Agents; Cell Survival; Diabetes Mellitus, Experimental; Heart; Humans; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxazoles; PPAR alpha; PPAR gamma; Protective Agents; Signal Transduction; Thiophenes | 2016 |